

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure 1. Demographics are not differentially associated with patient clusters.

AB) At DSO11, plasma concentration across four patient clusters of RBD-specific **A)** IgM or **B)** IgA. **CD)** MELD representations of local enrichment across PHATE embedding, of **C)** critical severity or **D)** fatal outcome. **E)** Days in hospital among survivors of patient clusters. **F)** Age of patients per patient cluster. **G)** Percentage of the whole cohort or per patient cluster which are female (hashed). **H)** Fraction of dominant ancestry per patient cluster, calculated from genotyping. N discovery cohort: 1 = 38; 2 = 49; 3 = 73; 4 = 82 (242 in total). **ABEF)** Kruskal-Wallis with Dunn's multiple comparison tests. **GH)** Chi2 tests.

Supplementary Figure 2. Kinetics of RBD-specific antibody responses per patient clusters. A)

RBD-specific IgG levels at DSO20 (+/- 4 days) per patient cluster. B) Sigmoidal curve fitted to the average per day per patient cluster of RBD-specific IgG responses, along day since symptom onset, within the validation cohort. **C)** RBD-specific IgG levels at DSO20 (+/- 4 days) per patient cluster of the validation cohort. **DE)** Model and statistical comparisons of RBD-specific **D)** IgM and **E)** IgA of the discovery cohort. **F)** Fraction of patients per cluster with at least one sample with detectable plasma vRNA (>13 copies/mL, saturated pie slices) throughout hospital stay. N discovery cohort: 1 = 38; 2 = 49; 3 = 73; 4 = 82 (242 in total). N validation cohort: V1 = 37; V2 = 39 (76 in total). **A)** Kruskal-Wallis with Dunn's multiple comparison tests. **B)** Mann-Whitney test. **DE)** Two-stage bootstrap, with 1000 simulations. Pairwise comparisons between all four clusters.

Supplementary Figure 3. Similar plasma profiles at DSO11 between different outcomes of cluster 1 patients. A)

Patients from PHATE embedding color-coded by outcome at DSO60, where mauve dots are fatal outcome, and pink dots are survivors. B-F) DSO11 levels, between survivors and non-survivors, of **B)** plasma vRNA; **C)** Cytokine score ; **D)** Tissue damage score and **E)** RBD-specific IgG ; **F)** ssGSEA COVID severity score. **G)** GSEA on Hallmark gene sets for the contrast survivor vs deceased within

cluster 1 only. **H-I)** Gene ontology (GO) enrichments for the Biological Processes (BP) database for significantly upregulated (FDR < 0.01, logFC > 0) genes for contrasts H) 1 vs 2 or I) 3 vs 4. Only significant enrichments (FDR < 0.05) are shown. **J-L)** At DSO11, correlation between IFN score and contemporaneous **J)** vRNA; **K)** Cytokine Score or **L)** Tissue damage score. BCDEFJKL) N: 1 = 38; 2 = 49 ; 3 = 73, 4 = 82 (242 in total). GHI). N: 1 = 37 ; 2 = 35 ; 3 = 41, 4 = 61 (174 in total).BCDEF) Mann-Whitney test. JKL) Spearman correlation.

Supplementary Figure 4. Distribution of isotypes among RBD-specific antibody secreting cells.

A) Representative gating strategy to identify B cells (CD19⁺ CD20⁺) or plasmablasts (CD19⁺/- CD20⁻ CD11c⁻ CD38⁺ CD27⁺). **B)** Representative gating strategy of RBD-specific PB per cluster. **C)** RBD gate on B cells from a convalescent subject. **D)** Frequency of B cells which are RBD-specific in all four acute COVID-19 clusters, uninfected donors (UC) or convalescent subjects (Conv). **E)** RBD gate on plasma cells from a convalescent subject. **F)** Frequency of PB cells which are RBD-specific in all four acute COVID-19 clusters, uninfected donors (UC), or convalescent subjects (Conv). n for cluster 1 = 14; 2 = 16; 3 = 12; 4 = 13; Conv = 3; UC = 5. **GH)** Correlation between ssGSEA COVID-19 severity score and absolute counts of RBD-specific G) B cells or H) PB. **IJ)** Pie chart of isotype expression among I) RBD-specific B cells or J) RBD-specific PB per patient clusters. n for cluster 1 = 14; 2 = 16; 3 = 12; 4 = 13. DF) Kruskal-Wallis with Dunn's multiple comparison tests. GH) Spearman correlations. IJ) Permutation test (1000 iterations).

Supplementary Figure 5. Spike-specific T cell responses in acute and resolved COVID-19.

A) PBMCs from acutely-SARS-CoV-2-infected individuals were stimulated with peptide pools of viral antigens (Spike – S , M or N) for 6hrs (addition of BFA 1 hour after stimulation). Representative gates on cytokine⁺ CD4⁺ or CD8⁺ T cells. **B)** Net frequency of SARS-CoV-2-specific CD4⁺ T cells, as calculated using a Boolean OR gate on CD69 vs CD40L, IFN γ , IL-2, IL-10, IL-17, or TNF α . **C)** Net frequency of SARS-CoV-2-specific CD8⁺ T cells, as calculated using a Boolean OR gate on CD69 vs

CD107a, IFN γ or TNF α . **D)** Following 9hrs stimulation of PBMCs with Spike peptide pool, representative gating strategy for identify CD4 $^+$ or CD8 $^+$ T cells using AIM panel. **EF)** Frequency of **E)** CD4 $^+$ T or **F)** CD8 $^+$ T cells which are Spike-specific in all four acute COVID-19 clusters, uninfected donors (UC), or convalescent subjects (Conv). **C)** n = 26 COVID-19+ acute samples (3 were excluded due to incomplete sampling). **EF)** n for cluster 1 = 11; 2 = 13; 3 = 9; 4 = 11; Conv = 5; UC = 5. **C)** Friedman test, with Dunn's multiple comparison test. **EF)** Kruskal-Wallis with Dunn's multiple comparison tests.









